← InSilico Medicine Cayman TopCo overview

InSilico Medicine Cayman TopCo vs Simulations Plus: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

InSilico Medicine Cayman TopCo (3696.HK)

Q2 2026
▲4

Insilico's AI drug platform wins big pharma deals and turns profitable

  • Two major pharma deals validate AI platform Insilico signed a $2.5B deal with SK Biopharmaceuticals and a $600M collaboration with Takeda, bringing near-term cash and potential milestones. These deals show major drugmakers trust Insilico's AI to discover new medicines, which can drive future revenue and profit.

    These are the largest new partnerships this period and directly boost demand for Insilico's platform.

  • First-half profit forecast and Phase III trial progress Insilico expects H1 2026 net profit of $33.5–39.5 million on revenue up ~280% to ~$105 million, driven by out-licensing. Its lead AI-designed drug Rentosertib entered Phase III for lung scarring, the first AI-derived asset to reach that stage. This shows the business can make money and advance drugs.

    Profitability and late-stage clinical progress are key new proof points that can re-rate the stock.

  • Added to healthcare tech index, attracting passive funds Insilico joined the Healthcare Technology and Innovation index, which can bring in automatic buying from funds that track it. This adds steady demand for the shares and raises the company's profile among institutional investors.

    Index inclusion is a new capital-flow catalyst that can support the share price.

  • Sector rebound and platform out-licensing trend The innovative drug sector rebounded, with China's out-licensing deals nearing $100 billion in H1 2026. Insilico's Takeda deal is cited as a landmark showing Chinese firms now license entire technology platforms, not just single drugs. This tailwind lifts sentiment for the whole sector, including Insilico.

    It explains the broader industry force behind Insilico's deal momentum and investor interest.

June 2026
▲4

Insilico's AI drug platform wins big pharma deals and turns profitable

  • Two major pharma deals validate AI platform Insilico signed a $2.5B deal with SK Biopharmaceuticals and a $600M collaboration with Takeda, bringing near-term cash and potential milestones. These deals show major drugmakers trust Insilico's AI to discover new medicines, which can drive future revenue and profit.

    These are the largest new partnerships this period and directly boost demand for Insilico's platform.

  • First-half profit forecast and Phase III trial progress Insilico expects H1 2026 net profit of $33.5–39.5 million on revenue up ~280% to ~$105 million, driven by out-licensing. Its lead AI-designed drug Rentosertib entered Phase III for lung scarring, the first AI-derived asset to reach that stage. This shows the business can make money and advance drugs.

    Profitability and late-stage clinical progress are key new proof points that can re-rate the stock.

  • Added to healthcare tech index, attracting passive funds Insilico joined the Healthcare Technology and Innovation index, which can bring in automatic buying from funds that track it. This adds steady demand for the shares and raises the company's profile among institutional investors.

    Index inclusion is a new capital-flow catalyst that can support the share price.

  • Sector rebound and platform out-licensing trend The innovative drug sector rebounded, with China's out-licensing deals nearing $100 billion in H1 2026. Insilico's Takeda deal is cited as a landmark showing Chinese firms now license entire technology platforms, not just single drugs. This tailwind lifts sentiment for the whole sector, including Insilico.

    It explains the broader industry force behind Insilico's deal momentum and investor interest.

Latest
▲4

Insilico's AI drug platform wins big pharma deals and turns profitable

  • Two major pharma deals validate AI platform Insilico signed a $2.5B deal with SK Biopharmaceuticals and a $600M collaboration with Takeda, bringing near-term cash and potential milestones. These deals show major drugmakers trust Insilico's AI to discover new medicines, which can drive future revenue and profit.

    These are the largest new partnerships this period and directly boost demand for Insilico's platform.

  • First-half profit forecast and Phase III trial progress Insilico expects H1 2026 net profit of $33.5–39.5 million on revenue up ~280% to ~$105 million, driven by out-licensing. Its lead AI-designed drug Rentosertib entered Phase III for lung scarring, the first AI-derived asset to reach that stage. This shows the business can make money and advance drugs.

    Profitability and late-stage clinical progress are key new proof points that can re-rate the stock.

  • Added to healthcare tech index, attracting passive funds Insilico joined the Healthcare Technology and Innovation index, which can bring in automatic buying from funds that track it. This adds steady demand for the shares and raises the company's profile among institutional investors.

    Index inclusion is a new capital-flow catalyst that can support the share price.

  • Sector rebound and platform out-licensing trend The innovative drug sector rebounded, with China's out-licensing deals nearing $100 billion in H1 2026. Insilico's Takeda deal is cited as a landmark showing Chinese firms now license entire technology platforms, not just single drugs. This tailwind lifts sentiment for the whole sector, including Insilico.

    It explains the broader industry force behind Insilico's deal momentum and investor interest.

Simulations Plus Inc (SLP)

Q3 2026
▲3▼1

Altaris buyout at $18.50 cash anchors SLP; old accounting probe resurfaces

  • Altaris to buy SLP for $375M all-cash Altaris agreed to acquire Simulations Plus for about $375 million, or $18.50 a share in cash — a 26% premium to the 60-day average price. The board unanimously approved it, with closing expected in late 2026. This sets a firm floor under the stock and is the main reason it trades near the deal price.

    The buyout is the single biggest force setting SLP's price now.

  • Agentic AI layer built with NVIDIA BioNeMo Simulations Plus is building an AI 'agent' layer for its Composer platform using NVIDIA's BioNeMo toolkit, expanding a May 2026 partnership. It aims to speed up drug-modeling workflows while keeping scientific results traceable. This supports the company's long-term technology story, though the pending buyout now matters more for the share price.

    It shows the technology value underpinning the company being acquired.

  • Q3 swing to profit on no impairment charge Simulations Plus reported Q3 net income of $3.58 million versus a $67.32 million loss a year earlier, which had included a $77.22 million write-down. Revenue rose 7% to $21.89 million, but adjusted earnings fell to $0.30 a share from $0.45. Profitability improved, yet the core business still shows pressure.

    It gives the latest financial health picture behind the buyout.

  • Investor investigation revives old accounting worries Johnson Fistel is investigating Simulations Plus over a 2025 revenue guidance cut, a large net loss, and the dismissal of auditor Grant Thornton, which flagged unresolved segment-reporting and internal-control issues. These are old disclosures, but the probe keeps the accounting overhang in view and is a real counterweight to the buyout news.

    It is the main risk factor that could complicate or delay the deal.

July 2026
▲3▼1

Altaris buyout at $18.50 cash anchors SLP; old accounting probe resurfaces

  • Altaris to buy SLP for $375M all-cash Altaris agreed to acquire Simulations Plus for about $375 million, or $18.50 a share in cash — a 26% premium to the 60-day average price. The board unanimously approved it, with closing expected in late 2026. This sets a firm floor under the stock and is the main reason it trades near the deal price.

    The buyout is the single biggest force setting SLP's price now.

  • Agentic AI layer built with NVIDIA BioNeMo Simulations Plus is building an AI 'agent' layer for its Composer platform using NVIDIA's BioNeMo toolkit, expanding a May 2026 partnership. It aims to speed up drug-modeling workflows while keeping scientific results traceable. This supports the company's long-term technology story, though the pending buyout now matters more for the share price.

    It shows the technology value underpinning the company being acquired.

  • Q3 swing to profit on no impairment charge Simulations Plus reported Q3 net income of $3.58 million versus a $67.32 million loss a year earlier, which had included a $77.22 million write-down. Revenue rose 7% to $21.89 million, but adjusted earnings fell to $0.30 a share from $0.45. Profitability improved, yet the core business still shows pressure.

    It gives the latest financial health picture behind the buyout.

  • Investor investigation revives old accounting worries Johnson Fistel is investigating Simulations Plus over a 2025 revenue guidance cut, a large net loss, and the dismissal of auditor Grant Thornton, which flagged unresolved segment-reporting and internal-control issues. These are old disclosures, but the probe keeps the accounting overhang in view and is a real counterweight to the buyout news.

    It is the main risk factor that could complicate or delay the deal.

Latest
▲3▼1

Altaris buyout at $18.50 cash anchors SLP; old accounting probe resurfaces

  • Altaris to buy SLP for $375M all-cash Altaris agreed to acquire Simulations Plus for about $375 million, or $18.50 a share in cash — a 26% premium to the 60-day average price. The board unanimously approved it, with closing expected in late 2026. This sets a firm floor under the stock and is the main reason it trades near the deal price.

    The buyout is the single biggest force setting SLP's price now.

  • Agentic AI layer built with NVIDIA BioNeMo Simulations Plus is building an AI 'agent' layer for its Composer platform using NVIDIA's BioNeMo toolkit, expanding a May 2026 partnership. It aims to speed up drug-modeling workflows while keeping scientific results traceable. This supports the company's long-term technology story, though the pending buyout now matters more for the share price.

    It shows the technology value underpinning the company being acquired.

  • Q3 swing to profit on no impairment charge Simulations Plus reported Q3 net income of $3.58 million versus a $67.32 million loss a year earlier, which had included a $77.22 million write-down. Revenue rose 7% to $21.89 million, but adjusted earnings fell to $0.30 a share from $0.45. Profitability improved, yet the core business still shows pressure.

    It gives the latest financial health picture behind the buyout.

  • Investor investigation revives old accounting worries Johnson Fistel is investigating Simulations Plus over a 2025 revenue guidance cut, a large net loss, and the dismissal of auditor Grant Thornton, which flagged unresolved segment-reporting and internal-control issues. These are old disclosures, but the probe keeps the accounting overhang in view and is a real counterweight to the buyout news.

    It is the main risk factor that could complicate or delay the deal.

© 2026 MarketIVWhy